Background: Rotavirus is a significant cause of morbidity and mortality in neonatal calves, leading to severe gastrointestinal and systemic illnesses. Current treatments primarily focus on symptomatic relief and prevention through vaccines, with limited use of antiviral agents. This article considers the issue of experiments using the antiviral agent Triazavirin in the treatment of rotavirus infection in calves, with tracking the amount of virus during the polymerase chain reaction examination in fecal samples.Methods: The experiment was conducted at a Mordovian Republican Veterinary Laboratory in the National Research Mordovian State University named after N.P. Ogarev (Republic of Mordovia, Russia), between February and March 2023. Two groups of calves, experimental and control, were assessed. The experimental group received Triazavirin orally at a dose of 500 mg per day for 7 days. Before and after the experiment, fecal samples were taken from experimental calves for the PCR study of the ribonucleic acid of group A rotaviruses.Results: Treatment with Triazavirin resulted in a reduction of the rotavirus load by an average of 35.2%. The PCR analyses before and after treatment indicated a substantial decrease in viral RNA in the majority of treated calves, with variable individual responses.Conclusions: Triazavirin demonstrates potential as an effective antiviral treatment for rotavirus in calves, reducing viral load and possibly improving clinical outcomes. The use of PCR provided a reliable method for monitoring viral levels, thereby facilitating effective management of this infectious disease.Keywords: Calves; Treatment; Digestive and Respiratory Organs; Antiviral Agent; Rotavirus; Treatment
Read full abstract